47 results on '"Schrumpf, E."'
Search Results
2. C01/162 Interferon α2b treatment in low activity hepatitis C infection
3. Proteomic Analysis of Liver Fibrotic Septa and Periportal Spaces in Primary Sclerosing Cholangitis, Primary Biliary Cholangitis and Alcoholic Liver Disease
4. Lipid Antigens in Bile from Patients with Liver Diseases Activate Natural Killer T Cells
5. Norursodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis: Results of a Phase II Dose Finding Study
6. Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing Cholangitis
7. P1190 : The role of NKT cells in a mouse model (NOD.C3C4) with spontaneous bile duct inflammation
8. O082 : The gut microbiota in primary sclerosing cholangitis differs from that of healthy controls and ulcerative colitis patients without biliary disease
9. P354 CHOLANGIOCYTES FROM PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS EXPRESS CD1D AND HUMAN CHOLANGIOCYTES PRESENT ANTIGENS TO NATURAL KILLER T CELLS
10. O133 NOVEL PROTEIN MARKERS IDENTIFIED IN BILE AND SERUM ARE ASSOCIATED WITH A DIAGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS, DISEASE SEVERITY, AND TRANSPLANT-FREE SURVIVAL
11. P363 ENHANCED LIVER FIBROSIS SCORE PREDICTS TRANSPLANT-FREE SURVIVAL IN PSC INDEPENDENTLY OF THE MAYO RISK SCORE
12. O5 PRIMARY SCLEROSING CHOLANGITIS FROM A GLOBAL PERSPECTIVE – A MULTICENTER, RETROSPECTIVE, OBSERVATIONAL STUDY OF THE INTERNATIONAL PSC STUDY GROUP
13. SAT-372 - Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing Cholangitis
14. SAT-347 - Lipid Antigens in Bile from Patients with Liver Diseases Activate Natural Killer T Cells
15. LB02 - Norursodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis: Results of a Phase II Dose Finding Study
16. PS092 - Proteomic Analysis of Liver Fibrotic Septa and Periportal Spaces in Primary Sclerosing Cholangitis, Primary Biliary Cholangitis and Alcoholic Liver Disease
17. 102 NOVEL SUSCEPTIBILITY LOCI FOR PRIMARY SCLEROSING CHOLANGITIS IDENTIFIED BY GENOME-WIDE ASSOCIATION AND REPLICATION ANALYSIS
18. 22 ELECTROSTATIC MODIFICATIONS OF THE HLA-DR P9 PEPTIDE-BINDING POCKET AND SUSCEPTIBILITY TO PRIMARY SCLEROSING CHOLANGITIS
19. [112] GENETIC VARIATION IN THE RECEPTOR-LIGAND PAIR NKG2D-MICA IS STRONGLY ASSOCIATED WITH DEVELOPMENT OF CHOLANGIOCARCINOMA IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
20. Time dependent neural network prognostic model for Primary Sclerosing Cholangitis (PSC)
21. New time dependent prognostic models for Primary Sclerosing Cholangitis (PSC)
22. Natural history of primary sclerosing cholangitis. A longterm follow-up study of 394 european primary sclerosing cholangitis patients
23. Secondary osteoporosis after liver transplantation
24. Outcome of primary sclerosing cholangitis. Analysis of long-term observation of 77 Norwegian patients
25. The significance of anti-HCV antibodies Measured in chronic liver disease
26. Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study
27. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
28. Survival after liver transplansplantation of patients with PBC in the Nordic countries: Comparison to expected survival 1. From another series of transplantations and 2. To an international trial of medical treatment
29. The frequency of cholangicarcinoma (CC) in primary sclerosing cholangitis (PSC)
30. Circulating secretory immunoglobulins of the A and M isotypes in chronic liver disease
31. Risk factors in primary sclerosing cholangitis
32. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
33. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
34. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci.
35. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue.
36. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis.
37. Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis.
38. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
39. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients.
40. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy.
41. Liver transplantation for primary sclerosing cholangitis.
42. Cholangiocarcinoma in situ in primary sclerosing cholangitis: diagnosis by brush cytology and treatment by liver transplantation.
43. Endoscopic treatment for primary sclerosing cholangitis?
44. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.
45. Liver steatosis in hypobetalipoproteinemia. A case report.
46. Measles and rubella antibodies in patients with chronic liver disease.
47. An autoantibody profile in primary sclerosing cholangitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.